Navigation Links
Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company
Date:1/7/2009

CLEARWATER, FL, Jan. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com the company is pleased to announce that it has identified a cosmetics company as a potential merger candidate. The cosmetics company also located in E Europe (Serbia) is engaged in online sales of the "Melem" product. Melem is a versatile, all-purpose skin and lip balm. It has a wide variety of skin and lip problems including eczema, psoriasis, chapped skin and lips, calluses, sunburns, insect bites and much more.

Andrea Rubio Zecevic, who currently acts as a head scientific advisor to HTDS said "Just to be clear, the Melem cosmetics company is not the core business of HTDS by any stretch of the imagination. It's a small self supporting cosmetics company and a nice add on for HTDS. The opportunities in this region due to the Balkan wars of the 1990s are enormous. There are various European Union reconstruction programs and enticements in place while the whole country is in the process of privatizing its entire infrastructure. Just to give our readers an example, HTDS will pay for the Melem cosmetics company a sum equivalent to a price of a USA based mid-sized car. This includes all the formulas, packaging the good will, the client base and whole back office. This is a fraction of the reproduction cost had we bought a similar company just 300-400 miles west in Switzerland or Austria or any other western European country. The company will complete the transaction on all cash basis. Currently this region of the world is celebrating the Orthodox Christmas. As soon as these holidays are behind them, we expect the final documents will be executed and the merger company name announced. In addition we are in contact with the Chief Scienist Dr. Sanja Pekovic who will shortly after the holidays commence furnishing us with regular updates on the progress her team has made with their work (see www.slavicabiochem.com for details). Our aspirations for the merger with the Chinese based medical company engaged in the similar research as Slavica continues. The synergies are definitely present. Our representatives will be in Beijing next week and we should have some preliminary news to report on that front as well."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
2. Kawasaki Disease Treated with Plasma-Derived Therapy
3. Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D.
4. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
5. First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center
6. Dr. Mitchell L. Petusevsky, M.D., F.C.C.P. Meets Growing Demand for the Treatment of Sleep and Pulmonary Disorders
7. New Addiction Treatment Program Allows You to Attend Drug Rehabilitation and Still Keep Your Day Job
8. New appropriate use criteria guide treatment of patients with heart blockage
9. Cell death from cytomegalovirus may bring new life to treatment of retinal disease
10. Hard To Treat Diseases (HTDS) Completes E Europe Merger
11. Molecular imaging enables earlier, individualized treatment of thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: